Pemetrexed for the treatment of malignant pleural mesothelioma

  • Technology appraisal guidance
  • TA135
  • Published: 
Download guidance (PDF)

8 Sources of evidence considered by the committee

A. The assessment report for this appraisal was prepared by Liverpool Reviews & Implementation Group, University of Liverpool. Dundar Y, Bagust A, Dickson R et al. Pemetrexed disodium for the treatment of malignant pleural mesothelioma: a systematic review and economic evaluation (December 2005)

B. The following organisations accepted the invitation to participate in this appraisal. They were invited to comment on the draft scope, assessment report, and the appraisal consultation document (ACD). Organisations listed in I and II were also invited to make written submissions and have the opportunity to appeal against the final appraisal determination.

I) Manufacturer/sponsor:

  • Eli Lilly and Company

II) Professional/specialist and patient/carer groups:

  • Asbestos Awareness Wales/UK

  • Asbestos Diseases UK

  • Association of Cancer Physicians

  • Association for Palliative Medicine of Great Britain

  • British Mesothelioma Interest Group (BMIG)

  • British Oncology Pharmacy Association

  • British Psychosocial Oncology Society

  • British Thoracic Society (Lung Cancer and Mesothelioma Working party)

  • Cancerbackup

  • Cancer Research UK

  • Cancer Voices

  • June Hancock Mesothelioma Research Fund

  • Long Term Medical Conditions Alliance

  • Macmillan Cancer Relief

  • Marie Curie Cancer Care

  • National Cancer Alliance

  • National Council for Palliative Care

  • National Lung Cancer Forum for Nurses

  • Occupational and Environmental Diseases Association

  • Ridings Asbestos Support and Awareness Group (RASAG)

  • Roy Castle Lung Cancer Foundation

  • Royal College of Nursing

  • Royal College of Physicians' Intercollegiate Lung Cancer Group

  • Royal College of Physicians' Medical Oncology Joint Special Committee

  • Royal College of Radiologists

  • Royal Pharmaceutical Society

  • Society of Cardiothoracic Surgeons of Great Britain and Ireland

  • Society of Radiographers

  • Tenovus Cancer Information Centre

III) Commentator organisations (without the right of appeal):

  • Approved Prescription Services (cisplatin)

  • Bristol-Myers Squibb Pharmaceuticals (cisplatin)

  • British National Formulary

  • British Thoracic Oncology Group

  • GMB Union

  • Institute of Cancer Research

  • Liverpool Reviews and Implementation Group

  • Mayne Pharma (cisplatin)

  • MRC Clinical Trials Unit

  • National Cancer Research Institute

  • National Coordinating Centre for Health Technology Assessment

  • National Public Health Service for Wales

  • NHS Confederation

  • NHS Purchasing and Supplies Agency

  • NHS Quality Improvement Scotland

  • Transport & General Workers Union

  • Welsh Assembly Government

C. The following individuals were selected from clinical specialist and patient advocate nominations from the non-manufacturer/sponsor consultees and commentators. They participated in the appraisal committee discussions and provided evidence to inform the appraisal committee's deliberations. They gave their expert personal view on pemetrexed for malignant pleural mesothelioma by attending the initial committee discussion and/or providing written evidence to the committee. They were also invited to comment on the ACD.

  • Dr Mary O'Brien, Consultant Medical Oncologist, Institute of Cancer Research, nominated by the Institute – clinical specialist

  • Dr Robin Rudd, Consultant Physician, British Thoracic Society, nominated by the British Thoracic Society – clinical specialist

  • Ms Liz Darlison, Consultant Nurse, Mesothelioma UK, nominated by June Hancock Mesothelioma Research Fund – patient expert

  • Macmillan Lung Nurse Specialist, Harrogate District Hospital, nominated by June Hancock Mesothelioma Research Fund
    – patient expert